GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MIC:REGN-RM) » Definitions » Cyclically Adjusted Price-to-FCF

Regeneron Pharmaceuticals (MIC:REGN-RM) Cyclically Adjusted Price-to-FCF : (As of Jul. 18, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Regeneron Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted Price-to-FCF for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Regeneron Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.67 42.70 38.07 39.41 27.90

Regeneron Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.30 44.09 42.51 27.90 23.64

Competitive Comparison of Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


;
;

Regeneron Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Regeneron Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Regeneron Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=574.772/134.9266*134.9266
=574.772

Current CPI (Mar. 2025) = 134.9266.

Regeneron Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 8.661 100.684 11.607
201509 423.215 100.392 568.803
201512 65.973 99.792 89.200
201603 -35.020 100.470 -47.030
201606 143.113 101.688 189.892
201609 288.397 101.861 382.015
201612 125.369 101.863 166.063
201703 148.557 102.862 194.865
201706 -43.704 103.349 -57.057
201709 175.695 104.136 227.645
201712 228.696 104.011 296.672
201803 268.781 105.290 344.438
201806 155.082 106.317 196.814
201809 197.405 106.507 250.080
201812 389.573 105.998 495.894
201903 462.341 107.251 581.649
201906 51.557 108.070 64.370
201909 240.524 108.329 299.578
201912 351.549 108.420 437.496
202003 365.032 108.902 452.267
202006 482.808 108.767 598.927
202009 -282.513 109.815 -347.116
202012 711.050 109.897 872.997
202103 380.001 111.754 458.794
202106 317.235 114.631 373.401
202109 2,104.522 115.734 2,453.516
202112 1,445.840 117.630 1,658.447
202203 1,819.077 121.301 2,023.412
202206 227.007 125.017 245.001
202209 -235.415 125.227 -253.650
202212 787.233 125.222 848.244
202303 718.423 127.348 761.178
202306 633.097 128.729 663.579
202309 777.522 129.860 807.861
202312 615.976 129.419 642.188
202403 1,073.765 131.776 1,099.436
202406 112.099 132.554 114.106
202409 818.355 133.029 830.029
202412 943.214 133.157 955.748
202503 574.772 134.927 574.772

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regeneron Pharmaceuticals  (MIC:REGN-RM) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Regeneron Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals Business Description

Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines